Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 10 Issue 3, June 2016

Volume 10 Issue 3

In this issue...

• Emerging viral epidemics catalyze vaccine dealmaking

• How do you value a pharmaceutical deal?

• Biopharma and academia explore new partnership models

• Inflammation in numbers

Cover image: Inspired by the feature discussing partnerships to fight Zika on page 15. Source: Centers for Disease Control and Prevention. Credit: Laura Marshall.

Academic partnering

    Feature

  • News Feature |

    Academic partnering is undergoing a period of great diversification and growth, with new forms of collaboration between academia and industry, such as the open innovation model, setting the stage for a fertile crop of partnerships.

    • Gaspar Taroncher-Oldenburg
  • Profiles

  • Advertisement Feature |

    The Center for Research and Advanced Studies (Cinvestav) is a national leader in scientific research, technology development and the formation of highly educated professionals in Mexico. Cinvestav is now expanding its reach globally with a nanoparticle-based therapy for Parkinson’s disease that represents an opportunity for international partnerships.

  • Advertisement Feature |

    By translating academic innovation and partnering with big pharma, the University of Dundee’s Drug Discovery Unit (DDU) is developing novel therapeutic targets to a stage where they can be smoothly transitioned across to the pharmaceutical industry.

  • Advertisement Feature |

    Combining its heritage in innovation with capabilities in clinical translational medicine, Ulster University has created a pipeline of promising licensing opportunities that target a number of therapeutic areas.

  • Advertisement Feature |

    Through its nimble Office of Therapeutics Alliances, NYU Langone Medical Center is harnessing the therapeutic potential of its world-class research by partnering with external experts in commercial drug discovery and development to advance the next generation of medical therapies and diagnostics.

  • Advertisement Feature |

    CALYM is a nonprofit research institute that offers a unique R&D approach in lymphoma treatments and diagnostics, spanning from new target identification to large international phase 3 clinical trials.

  • Advertisement Feature |

    The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, is a first-of-its-kind international center for research on and development of microbial and mammalian-cell–based production platforms.

Emerging viral epidemics catalyze vaccine dealmaking

    Feature

  • News Feature |

    Global viral threats such as Ebola and Zika have accelerated vaccine developers’ forays into public health and catalyzed new partnership strategies.

    • Chris Morrison
  • Profiles

  • Advertisement Feature |

    By mimicking the way viruses bind to host cells, NanoViricides is developing unique nanomedicines that are able to trick, trap and destroy these pathogens.

    • NanoViricides, Inc.
  • Advertisement Feature |

    Sanofi Pasteur, the vaccines division of Sanofi, is seeking partners with a common drive for excellence who will share the company’s pursuit of innovation.

  • Advertisement Feature |

    The Antibody Lab is launching BESTcell, a new system to make fast, stable mammalian cells for bioproduction.

  • Advertisement Feature |

    Helperby’s antibiotic-resistance breakers are a powerful tool serving to prolong and boost antibiotic efficacy and should help counter the growing global crisis of antibiotic resistance.

    • Helperby Therapeutics Ltd
  • Advertisement Feature |

    Now ready for partnering, Biotest’s IgM Concentrate could be a breakthrough therapy for patients with severe community-acquired pneumonia.

  • Advertisement Feature |

    With two marketed products, two successful technology platforms and two advanced clinical candidates, Valneva is fast becoming the leading independent vaccine company.

How do you value a pharmaceutical deal?

    Feature

  • News Feature |

    The pharmaceutical and biotechnology industries see over 3,000 deals signed every year, many of which involve the complex and often unfamiliar process of valuing potential products that are not yet on the market. In this feature, valuation specialists Venture Valuation explain how the value of a product is calculated and how this relates to the overall deal value.

    • Aitana Peire
    • Patrik Frei
  • Profiles

  • Advertisement Feature |

    Verseon’s unique computational platform is driving the identification and optimization of novel drug candidates for a broad range of indications.

Inflammation in numbers

    Feature

  • News Feature |

    Recently announced inflammation deals selected by BioPharma Dealmakers highlight the approaches companies are taking to target disorders in this area, specifically those affecting the gastrointestinal system.

    • Biopharma Dealmakers
  • Profiles

  • Advertisement Feature |

    Anatabine citrate, a cholinergic small molecule in development at Rock Creek Pharmaceuticals, offers a distinct alternative to existing nonsteroidal anti-inflammatory drugs (NSAIDs), steroids and biologics for the treatment of chronic and acute inflammatory diseases. The company is looking to partner for a phase 2 trial in psoriasis.

Search

Quick links